These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 10824627)

  • 1. Population pharmacokinetics and pharmacodynamics of TS-943 for selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist in normal healthy subjects.
    Furuya A; Kato N; Jingu S; Akimoto M; Higuchi S; Suwa T; Ogata H
    Clin Pharmacol Ther; 2000 May; 67(5):489-97. PubMed ID: 10824627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein-IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs.
    Furuya A; Nozawa M; Gotoh J; Jingu S; Akimoto M; Higuchi S; Suwa T; Ogata H
    J Pharm Pharmacol; 2002 Jul; 54(7):921-7. PubMed ID: 12162710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients.
    Mould D; Chapelsky M; Aluri J; Swagzdis J; Samuels R; Granett J
    Clin Pharmacol Ther; 2001 Apr; 69(4):210-22. PubMed ID: 11309549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PK/PD simulations as a tool for rational design of clinical dosage regimens: an example with Fradafiban.
    Brickl R; Heinzel G; Weisenberger H; Schubert H; Rutsch W; Roth W
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):475-80. PubMed ID: 9352399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers.
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Massignon D; Calic F; Sibille M; Kirkesseli S
    J Clin Pharmacol; 2000 Nov; 40(11):1245-56. PubMed ID: 11075310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
    Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
    J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetics of DMP 728, a platelet GPIIb/IIIa antagonist, in healthy subjects.
    Michaelis W; Turlapaty P; Gray J; Fiske WD; Faulkner E; Kornhauser D; Mousa SA
    Clin Pharmacol Ther; 1998 Mar; 63(3):384-92. PubMed ID: 9542482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
    Wittke B; Mackie IJ; Machin SJ; Timm U; Zell M; Goggin T
    Br J Clin Pharmacol; 1999 May; 47(5):521-30. PubMed ID: 10336576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
    Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
    Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
    Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
    Matsushima N; Jakubowski JA; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
    Platelets; 2006 Jun; 17(4):218-26. PubMed ID: 16769599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
    Quinn MJ; Cox D; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form.
    Refino CJ; Modi NB; Bullens S; Pater C; Lipari MT; Robarge K; Blackburn B; Beresini M; Weller T; Steiner B; Bunting S
    Thromb Haemost; 1998 Jan; 79(1):169-76. PubMed ID: 9459344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.
    Peerlinck K; De Lepeleire I; Goldberg M; Farrell D; Barrett J; Hand E; Panebianco D; Deckmyn H; Vermylen J; Arnout J
    Circulation; 1993 Oct; 88(4 Pt 1):1512-7. PubMed ID: 8403299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet Effect of a Pulaimab [Anti-GPIIb/IIIa F(ab)2 Injection] Evaluated by a Population Pharmacokinetic-pharmacodynamic Model.
    Liu YO; Wang ZN; Chen CY; Zhuang XH; Ruan CG; Zhou Y; Cui YM
    Curr Drug Metab; 2019; 20(13):1060-1072. PubMed ID: 31755383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers.
    Fossler MJ; Ebling WF; Ma S; Kornhauser D; Mondick J; Barrett JS; Garner D; Quon CY; Pieniaszek HJ
    J Clin Pharmacol; 2002 Dec; 42(12):1326-34. PubMed ID: 12463727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers.
    Greenberg HE; Wissel P; Barrett J; Barchowsky A; Gould R; Farrell D; Panebianco D; Hand E; Gillen L; Goldberg MR; Bjornsson TD
    J Clin Pharmacol; 2000 May; 40(5):496-507. PubMed ID: 10806603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.